Q2 Earnings Estimate for TNGX Issued By HC Wainwright

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities research analysts at HC Wainwright issued their Q2 2027 EPS estimates for Tango Therapeutics in a research note issued on Tuesday, August 18th. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.37) per share for the quarter. HC Wainwright has a “Buy” rating and a $68.00 price objective on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.54) EPS.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05).

Other equities research analysts have also recently issued reports about the stock. Leerink Partners lifted their price objective on shares of Tango Therapeutics from $55.00 to $69.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Stifel Nicolaus upped their price objective on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Canaccord Genuity Group lifted their price target on Tango Therapeutics from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Wedbush raised their price objective on shares of Tango Therapeutics from $19.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Finally, Wolfe Research set a $35.00 price objective on Tango Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 8th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.46.

Tango Therapeutics Stock Up 0.6%

Tango Therapeutics stock opened at $25.44 on Wednesday. Tango Therapeutics has a 52-week low of $6.25 and a 52-week high of $34.39. The company’s 50 day moving average is $28.69 and its two-hundred day moving average is $22.51. The firm has a market cap of $4.29 billion, a PE ratio of -29.93 and a beta of 1.16.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TNGX. Invesco Ltd. increased its holdings in Tango Therapeutics by 138.8% during the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock valued at $97,000 after acquiring an additional 40,983 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Tango Therapeutics in the first quarter valued at about $195,000. Dynamic Technology Lab Private Ltd grew its position in shares of Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after purchasing an additional 15,037 shares during the last quarter. Woodline Partners LP grew its position in shares of Tango Therapeutics by 28.3% in the first quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock valued at $693,000 after purchasing an additional 111,791 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Tango Therapeutics by 270.6% during the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock worth $483,000 after purchasing an additional 257,668 shares in the last quarter. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the sale, the insider owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.50% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.